AzTrials
AzTrials

Cervical Cancer ScreeningOptiTri_GCNCT07177170

Impact of a Single Versus Multiple Visits on the Cervical Cancer Screening Completeness, Feasibility and Acceptability Among Women Living With HIV in Cameroon

A study testing Differentiated screening delivery and Single visit in people with Cervical Cancer Screening and HIV, run by Institut de Recherche pour le Developpement at 1 site in Cameroon.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record

Search all trials

Trial summary

Context. Cervical cancer (CC) is a leading cause of death among women living with HIV (WLHIV) in resource-limited settings. Yet, effective methods for screening and preventing CC are available. Read more about this study

Who is it for?
Ages 25 to 49 years, women only
Conditions the study is for
Cervical Cancer Screening, HIV
What is being tested?
Differentiated screening delivery and Single visit
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,422 participants
Where
1 siteCameroon
Study dates
12 Dec 2024to May 2027
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 25 to 49 years
  • Women only
  • No healthy volunteers
  • Adult

Who may be able to join

  • HIV infection
  • receiving antiretroviral therapy
  • living in the department of the study hospital

Who cannot join

  • ongoing pregnancy
  • hysterectomy
  • treatment of cervical lesion in the past 12 months
  • Expected follow-up difficulties: planned absence that could interfere with the participation in the study (e.g., travel abroad, relocation, imminent transfer, etc.);
  • Any pathology or concomitant treatment which, in the opinion of the investigators, contraindicates participation or prevents satisfactory participation in the study Inclusion deferred if
  • menstrual bleeding
  • post-partum (<12 weeks after delivery)
  • clinicla signs of cervical or pelvic infection

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Andre-Pascal Goura, MD contact

+227679336464

cdpoptitri@gmail.com

Cameroon1 site, 1 recruiting
  • Foumban hospital

    Foumban

    Amadou NJIFOU NJIMAH, Prof, +227679161300, cdpoptitri@gmail.com

    Recruiting

Other trials in Cameroon

About this study

Official title: Optimizing Cervical Cancer Screening Strategies With HPV Testing Among Women Living With HIV in Cameroon: Feasibility, Acceptability, and Impact of a Single-visit Test and Treat Approach in a Hospital Center With an HPV Testing Platform

Context. Cervical cancer (CC) is a leading cause of death among women living with HIV (WLHIV) in resource-limited settings. Yet, effective methods for screening and preventing CC are available. The recommanded approach for CC screening is based on multiple steps, including initial test to detect human papillomavirus (HPV) infection, visual inspection to identify women with HPV at risk for precancerous lesion and treatment when required.

Dropout may occur at these different steps, compromising the success of the CC elimination strategy. Performing the all screening and treatment sequence in a single visit has been recommanded based on the results of a large South African trial. Yet, in many contexts, including those with limited resources, the screening and treatment activities are performed in multiple visites for logistical reasons, resulting in many dropouts. Strategies based on the differentiated prestation approaches, which propose a simplified management centered on the patients preferences, could guide the adaptation of the single-visit approach to account for contextual constraints while maintaining high effectiveness.

Read more

The OptiTri-GC study aims to design and assess the impact of a differentiated CC screen and treat strategy in a district hospital; It will assess both its implementation and its effectiveness based on the completeness at each stage of the screening cascade. In addition, it will also include three sub-studies designed to evaluate :

  • The performance of urinary HPV testing.
  • The performance of different methods to identify women requiring a treatment.
  • The risk of post-treatment cervical disease.

This study has two periods. During the first period, a single visit approach will be used while differentiated approach will be prepared using participatory research. During the second period, the differentiated approach will be implemented. The screening overall completeness will be compared between the two periods to assess the differentiated approach effectiveness.

The study will also assess the implementation of each screening strategy in terms of :

  • Success through the measure of fidelity, reach and completeness
  • Identification of adaptation, barriers and facilitating/leverage factors
  • Perception, feasibility and acceptability of the screening strategies (by patients and health care workers) It will assess the participants' stress levels during the screening process and to identify potential psychosocial support strategies and document the experience of WLHIV and health workers during the screening process and the post-treatment follow-up.

Other study objectives include :

  • To assess the performance of different methods to identify women requiring a treatment
  • To assess the performance of HPV testing on a urine sample compared with vaginal self-collected or cervical (clinician-collected) samples
  • To assess the efficacy of treatment in terms of post-treatment cervical lesions

Methodology. Participants will be WLHIV aged 25 to 49 and eligible for CC screening. Health care workers will also be invited to participate to the implementation research. The data collected will be quantitative and qualitative.

Read the detailed description

Context. Cervical cancer (CC) is a leading cause of death among women living with HIV (WLHIV) in resource-limited settings. There is compelling evidence that screening for human papillomavirus (HPV) infection by testing is a very sensitive method for identifying women at risk for precancerous lesions of the cervix. But since HPV infections are very common among WLHIV, it is necessary to have secondary triage to identify women who need to be treated.

The HPV-based screening approach includes multiple steps, and dropout may occur at these different steps, compromising the success of the CC elimination strategy. A single-visit screen and treat approach has been recommanded based on the results of a large South African trial. Yet, in many contexts, including those with limited resources, the screening and treatment activities are often performed in multiple visites for logistical reasons, resulting in many dropouts. Strategies based on the differentiated prestation approach, which propose a simplified management centered on the patients preferences, could guide the adaptation of the single-visit approach to account for contextual constraints while maintaining high effectiveness.

The OptiTri-GC study aims to design and assess the impact of a differentiated CC screen and treat strategy in a district hospital; It will assess both its implementation and its effectiveness based on the completeness at each stage of the screening cascade. In addition, it will also include three sub-studies designed to evaluate :

  • the performance of urinary HPV testing.
  • the performance of different post-HPV test triage options (partial genotyping, simple or Artifical Intelligence assisted visual inspection, methylation markers)
  • the risk of post-treatment cervical disease and the performance of different cure markers.

This will be a type 2 hybrid study that combines intervention research and implementation research. A quasi-experimental design ("before - after") combined with case study will be used for the effectiveness component of the research. During the first period, a single visit approach will be used while differentiated approach will be prepared using participatory research. During the second period, the differentiated approach will be implemented.

The general objective of this research is to assess the (cost-)effectiveness and implementation of different the two screening delivery strategies.

Main specific objectives include:

  • To assess the effectiveness of each implementation strategy (in terms of cascade completeness)
  • To assess the implementation of each strategy in terms of :
  • Success through the measure of fidelity, reach and completeness
  • Identification of adaptation, barriers and facilitating/leverage factors
  • Perception, feasibility and acceptability of the screening strategies (by patients and health care workers)
  • To assess the participants' stress levels during the screening process and to identify potential psychosocial support strategies
  • To document the experience of WLHIV and health workers during the screening process and the post-treatment follow-up.
  • To assess the performance of different triage methods among HPV+ participants (partial genotyping, simple or aided visual inspection, S5 methylation)
  • To assess the performance of HPV testing on a urine sample compared with vaginal self-collected or cervical (clinician-collected) samples
  • To assess the efficacy of thermal ablation treatment in terms of post-treatment cervical lesions

Methodology. The implementation research will combine quantitative and qualitative methods and will be based on the i-PARHIS model. Participants will be WLHIV aged 25 to 49 and eligible for CC screening. Health care workers will also be invited to participate to the implementation research. The data collected will be quantitative and qualitative. Biomedical data will be collected prospectively. The implementation data will combine routine monitoring data, cross-sectional surveys, interviews and observations. The analysis will be sequential or convergent depending on the stages of the project.

Being tested
Differentiated screening delivery, Single visit
Keywords
cervical cancer, screening, HIV, differentiated prestation, implementation, resource-limited setting, thermal ablation, HPV test
Medical subject headings
Uterine Cervical Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Differentiated screening deliveryOther

    More flexibility in the screening delivery will be offered. A decision aid process will be implemented to help the participants deciding between the two options.

  • Single visitOther

    All the steps of the screening (using HPV test) and of the treatment will be performed in a single visit (when possible).

Study groups in NCT07177170
Study groupRoleWhat they receive
Single visitActive comparatorAll women will be screened using a single-visit approach
Receives: Other: Single visit
Differentiated prestationExperimentalA more flexible screening approach will be offered based on the participants preference. After counseling (following the decision aid approach), participants may decide to performed the screening in two visits.
Receives: Other: Differentiated screening delivery

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Screening completeness

    Proportion of HPV+ participants completing all screening steps within 60 days of inclusion.

    Measured: 60 days post screening initiation

Secondary outcomes (5)
  1. Screening completeness 2

    Proportion of HPV+ participants completing all screening steps within 120 days of inclusion.

    Measured: 120 days post screening initiation

  2. Acceptability of the screening delivery strategy

    Questionnaire assessing the acceptability and using a 4 point Likert scale

    Measured: Baseline (screening)

  3. Triage performance

    Sensitivity, specificity of the triage option to detect CIN2+ and CIN3+ lesion

    Measured: Baseline (screening)

  4. Performance of urinary HPV test

    Concordance between HPV test results from urine samples and those from cervical specimen collected by the clinician

    Measured: Baseline (screeening)

  5. Post treatment cervical lesion

    Frequency of CIN2+ lesion 12 months after treatment and performance of the markers of cure (sensitivity and specificity)

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Sep 2025
  2. Study start12 Dec 2024
  3. Primary completionApr 2026 (estimated)
  4. Study completionMay 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Screening
Allocation
Non-randomised
Intervention model
Sequential
Model description
Quasi-experimental design ("before - after") combined with a case study
Masking
None (open label)
Enrolment
1,422 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07177170
Sponsor's protocol ID
IRD_2024_CEPED_OptiTri_GC
Other IDs
22SANIC204, ANRS-0467
Acronym
OptiTri_GC
Status last verified
Sep 2025
First submitted
22 Aug 2025
Last updated
16 Sep 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in